Work

Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models

Year: 2019

Type: article

Abstract: and/or XIAP inhibitors led to tumor growth inhibition and extended survival in DRA-resistant patient-derived xenografts. This strategy provides a precision medicine approach to overcome similar challenges with other protein-based cancer therapies.

Source: Science Advances

DOI: 10.1126/sciadv.aaw9162

Authors: Mandana T. Manzari, Gray R. Anderson, Kevin H. Lin, Ryan S. Soderquist, Merve Çakir, Mitchell Zhang, Chandler E. Moore, Rachel N. Skelton, Maréva Fèvre, Xinghai Li, Joseph J. Bellucci, Suzanne E. Wardell, Simone A. Costa, Kris C. Wood, Ashutosh Chilkoti

Institution: Duke University

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,500

Funders: National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Biomedical Imaging and Bioengineering

Awards: G1174881085, G351541287, Elastin Fusion Proteins, Thermally Targeted Drug Delivery by Elastin Biopolymers, Selectively targeting apoptosis in PIK3CA mutant colorectal cancers, G89171726, G9000043894, Cancer Center Support Grant (CCSG)

OpenAlex ID: W2971799124

FWCI: 0.644

Cites: 53

Cited by: 15

Related to: 10